Logan Bauer’s Post

IT'S HERE. January is my favorite issue of Market Scope's Ophthalmic Market Perspectives newsletter! We look back at the Top 10 stories in ophthalmology from the past year. Subscribe here: https://lnkd.in/gKGEEJtr It's always tough to whittle the list down to 10 contenders. With so many approvals, deals, and product launches, 2023 was a busy year for eye care! Bausch + Lomb, ZEISS Medical Technology, Roche, Aurion Biotech, and Astellas Pharma were among the industry players making news in 2023. Do you recall a big story that didn't make our list? Let me know in the comments. 👇 #ophthalmology #industrynews #drugapproval #productlaunch #2023trends

🔌 Innovating at the Intersection of Medicine and Technology ⚙️ In the ever-evolving field of medical devices, the integration of electrical systems is unlocking new possibilities for patient care. This Tech Talk between Holly Scott of the Mullings Group and David N Constantine of Juniper Biomedical, is a great reminder of how far the industry has come in improving patient outcomes, and the potential that still lies ahead. In the spirit of Copetition (Thanks Holly Scott) we help companies bring their innovative medical devices to life by combining advanced COMSOL modeling with rapid prototyping and rigorous testing. Whether it’s refining a concept or navigating the complexities of electrical design, we’re here to support every step of your device technology development journey. If you’re working on the next breakthrough in medical technology, let’s connect and explore how we can collaborate. #MedicalDevices #Neuromodulation #Electroceuticals #Bioelectronics #TechnologyDevelopment #COMSOL

📈 Market Insights: Interbody Fusion Cages Market Overview and Future Outlook The interbody fusion cages market is on a steady growth trajectory, expanding from $2.18 billion in 2023 to an expected $2.29 billion in 2024, with a CAGR of 4.8%. This growth is driven by key factors such as a growing geriatric population, increasing obesity rates, a rise in sports-related injuries, and advancements in hospital infrastructure. Looking ahead, the market is projected to reach $2.79 billion by 2028, with a CAGR of 5.1%. Growth will be fueled by the rising awareness of minimally invasive surgical procedures, an increase in spinal surgeries, more accidents, and a growing prevalence of degenerative diseases. North America currently leads the market, while the Asia-Pacific region is poised for the fastest growth, thanks to increasing healthcare investments and a rising demand for advanced surgical solutions. As the market continues to evolve, technological advancements and strategic collaborations are paving the way for significant growth opportunities. The future of spinal surgery looks promising! https://lnkd.in/ejtTgUcB #Healthcare #MedicalDevices #MarketGrowth #SpinalSurgery #InterbodyFusion

🔍 Exploring Dry AMD Landscape: Key Insights In July, Octavus Consulting delved into the fascinating world of ophthalmology, focusing on dry age-related macular degeneration (AMD). Our team meticulously crafted a landscape and profiling for this rare indication. Here are the key takeaways: ➡ Approved Molecules: ♦ A total of 3 molecules has received approval, with 2 specifically targeting Geographic Atrophy (GA). ♦Astellas Pharma secured FDA approval for Izervay in Aug 2023, raking in an impressive revenue of 💴66B (~$43M). Astellas Pharma is also evaluating ASP7317, a promising cell therapy in P-I trials. ♦Apellis Pharmaceuticals’ Syfovre gained FDA approval in Feb 2023, contributing to a revenue of around $275M. ➡Pathways and Players: ♦The landscape features 6 molecules, divided between the complement (2) and alternate pathways (4). ♦Notably, both Syfovre (Apellis Pharmaceuticals) and Izervay (Astellas Pharma) act as complement pathway inhibitors. ♦Other contenders include AstraZeneca’s Danicopan (P-II), Ionis Pharmaceuticals, Inc. & Roche’s RG6299 (P-II), Novartis’ Iptacopan (P-II), and GT005 (P-II). ➡Upcoming Approvals: 🎯Keep an 👀eye out for P-III ALK-001 by Alkeus Pharmaceuticals, Inc., expected to receive approval in Jan 2025. 🎯Stealth BioTherapeutics is also on the horizon with Elamipretide by 2027. 📥 Get the Landscape PDF: Comment below, and we’ll send you a high-quality landscape directly via DM. If you’re seeking a deeper dive into the dry AMD or ophthalmology space, feel free to reach out at bd@octavusconsulting.com to schedule a call. 🚀 Let’s make this knowledge go viral! Share your thoughts and insights. 🌟 #DryAMD #Ophthalmology #HealthcareInsights #PharmaTrends #pharmainsights #competitiveanalysis #intelligence #competitiveintelligence

In July, Octavus Consulting is navigating Ophthalmology as a theme! Dry Age-Related Macular Degeneration (AMD) affects the retina, and the person loses central vision. However, the condition does not affect the peripheral vision. It is one of the leading causes of vision loss in people 50 years and above. Today, let's look into the competitive landscape of Dry Age-Related Macular Degeneration (AMD). Draw insights from our meticulously prepared competitive landscape with a glimpse of assets from several biopharma companies working in Dry AMD. Our competitive landscape service provides comprehensive competitor mapping to keep you ahead of the curve all the time. With our thorough portfolio assessment, we keep you up-to-date on competitors' pipeline candidates and marketed products. Moreover, our competitive landscape offering includes a trend assessment to help understand the ever-evolving healthcare market. Open the doors to endless opportunities and growth by reaching out to us at bd@octavusconsulting.com #competitivelandscape #competitors #dryagerelatedmaculardegeneration #dryamd #competitorinsights #pcd #pipelinecandidates #biopharma #biotech #ophthalmology #octavusconsulting

Ablation Technology Market worth $9.62 billion by 2029 Download PDF Brochure:-https://lnkd.in/gCUv_DSc The global ablation technology market is projected to reach USD 9.62 billion by 2029 from USD 6.11 billion in 2024, at a CAGR of 9.5% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Johnson & Johnson  Medtronic  Boston Scientific   Abbott  AtriCure, Inc. 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 AngioDynamics, Webster Biosense Inc, CONMED Corporation Olympus Corporation Galil Medical Inc. Varian Medical Systems Pacific Inc Smith+Nephew St. Jude Medical Stryker Hologic, Inc. Merit Medical Systems, Inc. Accuray NeuWave Medical, Inc. Monteris Medical MedWaves, BTG plc Alpinion Medical Systems EDAP TMS Elekta Misonix, INSIGHTEC Ethicon, Inc. Endocare, Inc. Terumo Medical Corporation Siemens Healthineers C2 Therapeutics RF Medical Co., Ltd. Baylis Medical Merit Medical Systems, Inc. Theraclion LeMaitre Vascular ULC, Gynesonics, Inc. Lumenis JenaSurgical AccuVein Inc. #ablationtechnology #minimallyinvasivesurgery #cardiacablation #cancertreatment #medicaldevices

BREAKING NEWS 🚨 Boston Scientific to acquire Axonics, Inc. for over $3 Billion. In familiar fashion, these big announcements come prior to large industry meetings. The North American Neuromodulation Society (NANS) is coming up, and this is sure to be a topic of conversation. Prior to this acquisition, BSX acquired Relievant Medsystems, Inc. for an $850 million upfront cash payment. Acquisition season is upon us, and yes, the market is definitely heating up 🔥 #mergersandacquisitions #medicaldevices

Orthocell Ltd (ASX:OCC) has raised $17 million in a major institutional placement, setting the stage for a bold US launch of its nerve repair device, Remplir, targeting the US$1.6 billion American market. This funding will also support expansion into Europe, Canada, and Southeast Asia. Key Highlights: ✅ $17 million raised through institutional investors at A$0.60 per share. ✅ Funds to drive US launch, enhance manufacturing, and expand marketing reach. ✅ Over $35 million in cash reserves post-placement for global market strategy. Orthocell Chair, John Van Der Wielen, remarked, “This allows us to grow the USA market quicker, invest in volume manufacturing, and also speed up the progress of our promising pipeline products.” Orthocell is well on track for submitting its US market authorisation for Remplir by the end of 2024, aiming for FDA approval in early 2025. Paul Anderson #MedTech #RegenerativeMedicine #Orthocell #Innovation #GlobalExpansion

Future is here

Protembis GmbH successfully closes €30m #SeriesB Financing Round for the initiation of PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial. Aachen, Germany based Protembis have developed ProtEmbo - a catheter-based cerebral protection system to deflect embolic material away from the cerebrovascular circulation during leftsided heart procedures – in particular transcatheter aortic valve replacement (TAVR). The round was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture SGR S.p.A. and Germany-based TVF | TechVision Fonds.  “It reflects the fact that the field of cerebral embolic protection is buoyant, and that future growth will be driven by younger and lower risk patients who have zero tolerance for brain injury risk when selecting to undergo transcatheter aortic valve replacement.” Conrad Rasmus #Cardiovascular #SeriesB #Ventures #Investment #MedTech